Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
31.65
-0.18 (-0.57%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
January 09, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
November 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million
↗
November 20, 2025
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
↗
November 20, 2025
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Gets Booted in Latest Fund Update
↗
November 19, 2025
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
↗
November 19, 2025
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Via
The Motley Fool
Why Bain Capital Is Selling Shares of This Biotech Stock Now
↗
November 18, 2025
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
October 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)
↗
October 20, 2025
Via
Benzinga
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 24, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts
↗
August 25, 2025
Via
Benzinga
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
August 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
August 18, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co
↗
August 07, 2025
Via
Benzinga
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
↗
August 06, 2025
Via
The Motley Fool
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 06, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
July 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
July 22, 2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th –
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
What Analysts Are Saying About NewAmsterdam Pharma Co Stock
↗
June 12, 2025
Via
Benzinga
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
↗
June 09, 2025
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
Via
Benzinga
Get insights into the top gainers and losers of Monday's pre-market session.
↗
June 09, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
June 09, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
June 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
May 27, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
May 14, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 08, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
